PME and JHX shares: 2 ASX shares to watch

The Pro Medicus Ltd (ASX:PME) share price has decreased 25.4% since the start of 2025. It's probably worth asking, 'is the PME share price good value?'
The Pro Medicus Ltd (ASX:PME) share price has decreased 25.4% since the start of 2025. Meanwhile, the James Hardie Industries plc (ASX:JHX) share price is 46.7% away from its 52-week high.

PME share price in focus

Founded in 1983, Pro Medicus is a provider of radiology IT software serving hospitals, imaging centres and healthcare groups worldwide.

The company’s suite of products focuses on Radiology Information Systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualization solutions. These tools support various functions, from patient scheduling and billing to rapid medical imaging interpretation and analysis.

Pro Medicus’ key value proposition lies in its flagship Visage software, which enables radiologists to remotely view large image files generated by X-rays on mobile devices. This capability allows diagnostic decisions to be made on-the-go, potentially improving patient outcomes by providing timely and accessible information.

JHX shares

James Hardie Industries is a building solutions company and the world’s largest producer of fibre cement and gypsum products.

The company operates across North America, Europe, Australia, and New Zealand with a team of more than 5,200 employees.

The main selling point of fibre cement for buildings is that the product doesn’t burn, is resistant to water and termite damage, and is durable and requires low maintenance.

PME & JHX share price valuation

As a growth company, some of the trends we might investigate from PME include revenue growth, profit growth, and return on equity (ROE). These measures can indicate the growth rates and prospects of the company, as well as their ability to generate returns from their assets.

Since 2021, PME has grown revenue at a rate of 33.4% per year to reach $162m in FY24. Over the same stretch of time, net profit has increased from $31m to $83m. As for ROE, PME last reported a ROE of 50.7%.

Over the last 3 years, JHX has increased revenue at a rate of 10.6% per year to hit $3,936m in FY24. Meanwhile, net profit has increased from $263m to $510m. As for ROE, JHX’s last reported figure was 29.4%.

Please keep in mind that context is important. These metrics give us some indication of company performance, but it’s just the start of valuing PME or JHX shares. To learn more about valuation, check out one of our free online investing courses.

Better investing starts here.

Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best  insights.

5%+ in passive income

Owen Rask’s investing report available

With bond ETFs like ASX:IAF and the S&P 500 riding high, now could be one of the best times to start earning passive income from a portfolio of shares and ETFs.

In this free analyst report, our Chief Investment Officer, Owen Rask, names 10 ASX stocks and ETFs to watch.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Skip to content